Determine the necessary mass, volume, or concentration for preparing a solution.
Activity Type | Activity Value -log(M) | Mechanism of Action | Activity Reference | Publications (PubMed IDs) |
---|
SKU | Size | Availability | Price | Qty |
---|---|---|---|---|
B407849-1ml | 1ml | Available within 4-8 weeks(?) Items will be manufactured post-order and can take 4-8 weeks. Thank you for your patience! | $352.90 |
FGFR1 Selective Inhibitors
Specifications & Purity | Moligand™, 10mM in DMSO |
---|---|
Biochemical and Physiological Mechanisms | Brivanib is an ATP-competitive inhibitor against VEGFR2 with IC50 of 25 nM, moderate potency against VEGFR-1 and FGFR-1, but >240-fold against PDGFR-β. Phase 3. |
Storage Temp | Store at -80°C |
Shipped In | Ice chest + Ice pads |
Grade | Moligand™ |
Product Description | Information Brivanib is an ATP-competitive inhibitor againstVEGFR2withIC50of 25 nM, moderate potency against VEGFR-1 and FGFR-1, but >240-fold against PDGFR-β. Phase 3. In vivo
cell lines: Concentrations: Incubation Time: Powder Purity:≥95% |
Activity Type | Activity Value -log(M) | Mechanism of Action | Activity Reference | Publications (PubMed IDs) |
---|
Activity Type | Activity Value -log(M) | Mechanism of Action | Activity Reference | Publications (PubMed IDs) |
---|
Activity Type | Activity Value -log(M) | Mechanism of Action | Activity Reference | Publications (PubMed IDs) |
---|
Activity Type | Activity Value -log(M) | Mechanism of Action | Activity Reference | Publications (PubMed IDs) |
---|
Activity Type | Activity Value -log(M) | Mechanism of Action | Activity Reference | Publications (PubMed IDs) |
---|
Activity Type | Activity Value -log(M) | Mechanism of Action | Activity Reference | Publications (PubMed IDs) |
---|
Canonical SMILES | CC(O)COC1=C[N]2N=CN=C(OC3=C(F)C4=C([NH]C(=C4)C)C=C3)C2=C1C |
---|---|
Molecular Weight | 370.38 |
Enter Lot Number to search for COA:
Solubility | Solubility (25°C) In vitro DMSO: 49 mg/mL (198.14 mM); Ethanol: 49 mg/mL (198.14 mM); Water: Insoluble; |
---|